Corcept Therapeutics Incorporated (NASDAQ: CORT) Stock Competitors & Peer Comparison
See CORT's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for CORT and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CORT | $80.53 | -6.31% | 8.8B | 231.69 | $0.35 | N/A |
| RPRX | $66.77 | +1.27% | 29.9B | 12.80 | $5.25 | +1.38% |
| WBA | $11.98 | +0.50% | 10.4B | -1.64 | -$7.29 | +4.17% |
| KNSA | $91.07 | -6.65% | 7.2B | 70.96 | $1.30 | N/A |
| LQDA | $42.00 | -6.65% | 4B | 32.91 | $1.37 | N/A |
| PBH | $49.89 | +2.34% | 2.3B | 11.10 | $4.42 | N/A |
| HROWL | $25.61 | +0.19% | 1.4B | N/A | N/A | N/A |
| HROWM | $26.03 | -0.08% | 1.3B | N/A | N/A | N/A |
| LTGO | $13.67 | -12.03% | 836.1M | -5.52 | -$2.52 | N/A |
| HELP | $8.94 | -16.52% | 656.7M | -2.54 | -$4.16 | N/A |
Stock Comparison
Royalty Pharma plc (NASDAQ: RPRX)
CORT vs RPRX Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, RPRX has a market cap of 29.9B. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while RPRX trades at $66.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas RPRX's P/E ratio is 12.80. In terms of profitability, CORT's ROE is +0.08%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, CORT is more volatile compared to RPRX. This indicates higher risk in terms of short-term price fluctuations for CORT.Check RPRX's competition here
Walgreens Boots Alliance, Inc. (NASDAQ: WBA)
CORT vs WBA Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while WBA trades at $11.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas WBA's P/E ratio is -1.64. In terms of profitability, CORT's ROE is +0.08%, compared to WBA's ROE of -0.57%. Regarding short-term risk, CORT is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for CORT.Check WBA's competition here
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA)
CORT vs KNSA Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, KNSA has a market cap of 7.2B. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while KNSA trades at $91.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas KNSA's P/E ratio is 70.96. In terms of profitability, CORT's ROE is +0.08%, compared to KNSA's ROE of +0.17%. Regarding short-term risk, CORT is less volatile compared to KNSA. This indicates lower risk in terms of short-term price fluctuations for CORT.Check KNSA's competition here
Liquidia Corporation (NASDAQ: LQDA)
CORT vs LQDA Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, LQDA has a market cap of 4B. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while LQDA trades at $42.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas LQDA's P/E ratio is 32.91. In terms of profitability, CORT's ROE is +0.08%, compared to LQDA's ROE of +1.50%. Regarding short-term risk, CORT is less volatile compared to LQDA. This indicates lower risk in terms of short-term price fluctuations for CORT.Check LQDA's competition here
Prestige Consumer Healthcare Inc. (NYSE: PBH)
CORT vs PBH Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, PBH has a market cap of 2.3B. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while PBH trades at $49.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas PBH's P/E ratio is 11.10. In terms of profitability, CORT's ROE is +0.08%, compared to PBH's ROE of +0.09%. Regarding short-term risk, CORT is more volatile compared to PBH. This indicates higher risk in terms of short-term price fluctuations for CORT.Check PBH's competition here
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL)
CORT vs HROWL Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while HROWL trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas HROWL's P/E ratio is N/A. In terms of profitability, CORT's ROE is +0.08%, compared to HROWL's ROE of -1.04%. Regarding short-term risk, CORT is more volatile compared to HROWL. This indicates higher risk in terms of short-term price fluctuations for CORT.Check HROWL's competition here
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM)
CORT vs HROWM Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while HROWM trades at $26.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas HROWM's P/E ratio is N/A. In terms of profitability, CORT's ROE is +0.08%, compared to HROWM's ROE of -1.04%. Regarding short-term risk, CORT is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for CORT.Check HROWM's competition here
Latigo Biotherapeutics Inc. (NASDAQ: LTGO)
CORT vs LTGO Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, LTGO has a market cap of 836.1M. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while LTGO trades at $13.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas LTGO's P/E ratio is -5.52. In terms of profitability, CORT's ROE is +0.08%, compared to LTGO's ROE of N/A. Regarding short-term risk, CORT is less volatile compared to LTGO. This indicates lower risk in terms of short-term price fluctuations for CORT.Check LTGO's competition here
Helus Pharma Inc. (NASDAQ: HELP)
CORT vs HELP Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, HELP has a market cap of 656.7M. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while HELP trades at $8.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas HELP's P/E ratio is -2.54. In terms of profitability, CORT's ROE is +0.08%, compared to HELP's ROE of -0.71%. Regarding short-term risk, CORT is less volatile compared to HELP. This indicates lower risk in terms of short-term price fluctuations for CORT.Check HELP's competition here
Sinovac Biotech Ltd. (NASDAQ: SVA)
CORT vs SVA Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, SVA has a market cap of 464.9M. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while SVA trades at $6.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas SVA's P/E ratio is -5.68. In terms of profitability, CORT's ROE is +0.08%, compared to SVA's ROE of -0.01%. Regarding short-term risk, CORT is more volatile compared to SVA. This indicates higher risk in terms of short-term price fluctuations for CORT.Check SVA's competition here
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL)
CORT vs CUVL Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, CUVL has a market cap of 252.4M. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while CUVL trades at $4.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas CUVL's P/E ratio is 10.79. In terms of profitability, CORT's ROE is +0.08%, compared to CUVL's ROE of N/A. Regarding short-term risk, CORT is less volatile compared to CUVL. This indicates lower risk in terms of short-term price fluctuations for CORT.Check CUVL's competition here
High Tide Inc. (NASDAQ: HITI)
CORT vs HITI Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, HITI has a market cap of 229.5M. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while HITI trades at $2.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas HITI's P/E ratio is -9.51. In terms of profitability, CORT's ROE is +0.08%, compared to HITI's ROE of -0.36%. Regarding short-term risk, CORT is less volatile compared to HITI. This indicates lower risk in terms of short-term price fluctuations for CORT.Check HITI's competition here
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI)
CORT vs CELG-RI Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, CELG-RI has a market cap of 198.1M. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while CELG-RI trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, CORT's ROE is +0.08%, compared to CELG-RI's ROE of +0.44%. Regarding short-term risk, CORT is more volatile compared to CELG-RI. This indicates higher risk in terms of short-term price fluctuations for CORT.Check CELG-RI's competition here
Electra Therapeutics Inc. (NASDAQ: ETRA)
CORT vs ETRA Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, ETRA has a market cap of 170.8M. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while ETRA trades at $7.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas ETRA's P/E ratio is -3.04. In terms of profitability, CORT's ROE is +0.08%, compared to ETRA's ROE of N/A. Regarding short-term risk, CORT is less volatile compared to ETRA. This indicates lower risk in terms of short-term price fluctuations for CORT.Check ETRA's competition here
TRex Bio Inc. (NASDAQ: TRXB)
CORT vs TRXB Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, TRXB has a market cap of 112.6M. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while TRXB trades at $13.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas TRXB's P/E ratio is -5.47. In terms of profitability, CORT's ROE is +0.08%, compared to TRXB's ROE of N/A. Regarding short-term risk, CORT is more volatile compared to TRXB. This indicates higher risk in terms of short-term price fluctuations for CORT.Check TRXB's competition here
Atlantic International Corp. (NASDAQ: ATLN)
CORT vs ATLN Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, ATLN has a market cap of 68.6M. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while ATLN trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas ATLN's P/E ratio is -0.68. In terms of profitability, CORT's ROE is +0.08%, compared to ATLN's ROE of -83.20%. Regarding short-term risk, CORT is less volatile compared to ATLN. This indicates lower risk in terms of short-term price fluctuations for CORT.Check ATLN's competition here
Citius Oncology, Inc. (NASDAQ: CTOR)
CORT vs CTOR Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, CTOR has a market cap of 52.4M. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while CTOR trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas CTOR's P/E ratio is -1.20. In terms of profitability, CORT's ROE is +0.08%, compared to CTOR's ROE of -1.03%. Regarding short-term risk, CORT is less volatile compared to CTOR. This indicates lower risk in terms of short-term price fluctuations for CORT.Check CTOR's competition here
Retension Pharmaceuticals Inc. (NASDAQ: RTSN)
CORT vs RTSN Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, RTSN has a market cap of 43.8M. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while RTSN trades at $11.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas RTSN's P/E ratio is -4.47. In terms of profitability, CORT's ROE is +0.08%, compared to RTSN's ROE of N/A. Regarding short-term risk, CORT is less volatile compared to RTSN. This indicates lower risk in terms of short-term price fluctuations for CORT.Check RTSN's competition here
Rite Aid Corporation (NYSE: RAD)
CORT vs RAD Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while RAD trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas RAD's P/E ratio is -0.05. In terms of profitability, CORT's ROE is +0.08%, compared to RAD's ROE of +2.76%. Regarding short-term risk, CORT is less volatile compared to RAD. This indicates lower risk in terms of short-term price fluctuations for CORT.Check RAD's competition here
Damora Therapeutics, Inc. (NASDAQ: GLTO)
CORT vs GLTO Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while GLTO trades at $21.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas GLTO's P/E ratio is -1.78. In terms of profitability, CORT's ROE is +0.08%, compared to GLTO's ROE of -0.83%. Regarding short-term risk, CORT is less volatile compared to GLTO. This indicates lower risk in terms of short-term price fluctuations for CORT.Check GLTO's competition here
Cosmos Health Inc. (NASDAQ: COSM)
CORT vs COSM Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, COSM has a market cap of 31.1M. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while COSM trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas COSM's P/E ratio is -0.42. In terms of profitability, CORT's ROE is +0.08%, compared to COSM's ROE of -1.19%. Regarding short-term risk, CORT is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for CORT.Check COSM's competition here
Nasus Pharma Ltd. (AMEX: NSRX)
CORT vs NSRX Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, NSRX has a market cap of 27.2M. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while NSRX trades at $3.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas NSRX's P/E ratio is -4.39. In terms of profitability, CORT's ROE is +0.08%, compared to NSRX's ROE of -1.59%. Regarding short-term risk, CORT is less volatile compared to NSRX. This indicates lower risk in terms of short-term price fluctuations for CORT.Check NSRX's competition here
SCYNEXIS, Inc. (NASDAQ: SCYX)
CORT vs SCYX Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, SCYX has a market cap of 23.7M. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while SCYX trades at $3.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas SCYX's P/E ratio is -1.10. In terms of profitability, CORT's ROE is +0.08%, compared to SCYX's ROE of -0.21%. Regarding short-term risk, CORT is less volatile compared to SCYX. This indicates lower risk in terms of short-term price fluctuations for CORT.Check SCYX's competition here
Pomdoctor Limited (NASDAQ: POM)
CORT vs POM Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, POM has a market cap of 13.1M. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while POM trades at $1.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas POM's P/E ratio is -0.22. In terms of profitability, CORT's ROE is +0.08%, compared to POM's ROE of +0.80%. Regarding short-term risk, CORT is less volatile compared to POM. This indicates lower risk in terms of short-term price fluctuations for CORT.Check POM's competition here
Biofrontera Inc. (NASDAQ: BFRI)
CORT vs BFRI Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, BFRI has a market cap of 13M. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while BFRI trades at $0.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas BFRI's P/E ratio is -1.59. In terms of profitability, CORT's ROE is +0.08%, compared to BFRI's ROE of -1.28%. Regarding short-term risk, CORT is less volatile compared to BFRI. This indicates lower risk in terms of short-term price fluctuations for CORT.Check BFRI's competition here
Cerenome, Inc. (NASDAQ: CNSY)
CORT vs CNSY Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, CNSY has a market cap of 12.8M. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while CNSY trades at $1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas CNSY's P/E ratio is -0.40. In terms of profitability, CORT's ROE is +0.08%, compared to CNSY's ROE of -3.94%. Regarding short-term risk, CORT is less volatile compared to CNSY. This indicates lower risk in terms of short-term price fluctuations for CORT.Check CNSY's competition here
China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD)
CORT vs CJJD Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while CJJD trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas CJJD's P/E ratio is -0.46. In terms of profitability, CORT's ROE is +0.08%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, CORT is less volatile compared to CJJD. This indicates lower risk in terms of short-term price fluctuations for CORT.Check CJJD's competition here
SunLink Health Systems, Inc. (AMEX: SSY)
CORT vs SSY Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while SSY trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas SSY's P/E ratio is -2.86. In terms of profitability, CORT's ROE is +0.08%, compared to SSY's ROE of -0.09%. Regarding short-term risk, CORT is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for CORT.Check SSY's competition here
Scienture Holdings, Inc. (NASDAQ: SCNX)
CORT vs SCNX Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, SCNX has a market cap of 5.3M. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while SCNX trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas SCNX's P/E ratio is -1.55. In terms of profitability, CORT's ROE is +0.08%, compared to SCNX's ROE of -0.54%. Regarding short-term risk, CORT is less volatile compared to SCNX. This indicates lower risk in terms of short-term price fluctuations for CORT.Check SCNX's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMS)
CORT vs BGMS Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, BGMS has a market cap of 5M. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while BGMS trades at $0.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas BGMS's P/E ratio is -0.25. In terms of profitability, CORT's ROE is +0.08%, compared to BGMS's ROE of -0.32%. Regarding short-term risk, CORT is more volatile compared to BGMS. This indicates higher risk in terms of short-term price fluctuations for CORT.Check BGMS's competition here
Eocene Ltd. (NASDAQ: EOCN)
CORT vs EOCN Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, EOCN has a market cap of 3.1M. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while EOCN trades at $2.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas EOCN's P/E ratio is -0.22. In terms of profitability, CORT's ROE is +0.08%, compared to EOCN's ROE of N/A. Regarding short-term risk, CORT is less volatile compared to EOCN. This indicates lower risk in terms of short-term price fluctuations for CORT.Check EOCN's competition here
MedAvail Holdings, Inc. (NASDAQ: MDVL)
CORT vs MDVL Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while MDVL trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas MDVL's P/E ratio is -0.05. In terms of profitability, CORT's ROE is +0.08%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, CORT is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for CORT.Check MDVL's competition here
Paranovus Entertainment Technology Ltd. (NASDAQ: PAVS)
CORT vs PAVS Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, PAVS has a market cap of 2.8M. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while PAVS trades at $3.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas PAVS's P/E ratio is -0.04. In terms of profitability, CORT's ROE is +0.08%, compared to PAVS's ROE of -0.46%. Regarding short-term risk, CORT is less volatile compared to PAVS. This indicates lower risk in terms of short-term price fluctuations for CORT.Check PAVS's competition here
ETHZilla Corporation Warrant (NASDAQ: ATNFW)
CORT vs ATNFW Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while ATNFW trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas ATNFW's P/E ratio is N/A. In terms of profitability, CORT's ROE is +0.08%, compared to ATNFW's ROE of -2.15%. Regarding short-term risk, CORT is less volatile compared to ATNFW. This indicates lower risk in terms of short-term price fluctuations for CORT.Check ATNFW's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMSP)
CORT vs BGMSP Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while BGMSP trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, CORT's ROE is +0.08%, compared to BGMSP's ROE of -0.32%. Regarding short-term risk, CORT is less volatile compared to BGMSP. This indicates lower risk in terms of short-term price fluctuations for CORT.Check BGMSP's competition here
AstraZeneca PLC ADRhedged (AMEX: AZNH)
CORT vs AZNH Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while AZNH trades at $53.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas AZNH's P/E ratio is 38.35. In terms of profitability, CORT's ROE is +0.08%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, CORT is more volatile compared to AZNH. This indicates higher risk in terms of short-term price fluctuations for CORT.Check AZNH's competition here
Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP)
CORT vs ASBP Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, ASBP has a market cap of 944.9K. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while ASBP trades at $7.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas ASBP's P/E ratio is -0.34. In terms of profitability, CORT's ROE is +0.08%, compared to ASBP's ROE of +19.93%. Regarding short-term risk, CORT is less volatile compared to ASBP. This indicates lower risk in terms of short-term price fluctuations for CORT.Check ASBP's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
CORT vs BFRIW Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, BFRIW has a market cap of 796.7K. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while BFRIW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas BFRIW's P/E ratio is N/A. In terms of profitability, CORT's ROE is +0.08%, compared to BFRIW's ROE of -1.28%. Regarding short-term risk, CORT is more volatile compared to BFRIW. This indicates higher risk in terms of short-term price fluctuations for CORT.Check BFRIW's competition here
Leafly Holdings, Inc. (NASDAQ: LFLYW)
CORT vs LFLYW Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while LFLYW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, CORT's ROE is +0.08%, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, CORT is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for CORT.Check LFLYW's competition here
Aspire Biopharma Holdings, Inc. (NASDAQ: ASBPW)
CORT vs ASBPW Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, ASBPW has a market cap of 149.5K. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while ASBPW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas ASBPW's P/E ratio is N/A. In terms of profitability, CORT's ROE is +0.08%, compared to ASBPW's ROE of +19.93%. Regarding short-term risk, CORT is more volatile compared to ASBPW. This indicates higher risk in terms of short-term price fluctuations for CORT.Check ASBPW's competition here
ProPhase Labs, Inc. (NASDAQ: PRPH)
CORT vs PRPH Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, PRPH has a market cap of 107.9K. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while PRPH trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas PRPH's P/E ratio is N/A. In terms of profitability, CORT's ROE is +0.08%, compared to PRPH's ROE of -13.59%. Regarding short-term risk, CORT is less volatile compared to PRPH. This indicates lower risk in terms of short-term price fluctuations for CORT.Check PRPH's competition here
POZEN Inc. (NASDAQ: POZN)
CORT vs POZN Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, POZN has a market cap of 0. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while POZN trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas POZN's P/E ratio is N/A. In terms of profitability, CORT's ROE is +0.08%, compared to POZN's ROE of +0.61%. Regarding short-term risk, CORT is less volatile compared to POZN. This indicates lower risk in terms of short-term price fluctuations for CORT.Check POZN's competition here
Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD)
CORT vs CPD Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, CPD has a market cap of 0. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while CPD trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas CPD's P/E ratio is N/A. In terms of profitability, CORT's ROE is +0.08%, compared to CPD's ROE of N/A. Regarding short-term risk, CORT is more volatile compared to CPD. This indicates higher risk in terms of short-term price fluctuations for CORT.Check CPD's competition here
Shire plc (NASDAQ: SHPG)
CORT vs SHPG Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, SHPG has a market cap of 0. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while SHPG trades at $179.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas SHPG's P/E ratio is 11.35. In terms of profitability, CORT's ROE is +0.08%, compared to SHPG's ROE of +0.13%. Regarding short-term risk, CORT is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for CORT.Check SHPG's competition here
Express Scripts Holding Company (NASDAQ: ESRX)
CORT vs ESRX Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, ESRX has a market cap of 0. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while ESRX trades at $92.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas ESRX's P/E ratio is 10.69. In terms of profitability, CORT's ROE is +0.08%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, CORT is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for CORT.Check ESRX's competition here
Impax Laboratories, Inc. (NASDAQ: IPXL)
CORT vs IPXL Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, IPXL has a market cap of 0. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while IPXL trades at $18.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas IPXL's P/E ratio is -10.11. In terms of profitability, CORT's ROE is +0.08%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, CORT is less volatile compared to IPXL. This indicates lower risk in terms of short-term price fluctuations for CORT.Check IPXL's competition here
Orexigen Therapeutics, Inc. (NASDAQ: OREX)
CORT vs OREX Comparison November 2026
Corcept Therapeutics Incorporated (NASDAQ: CORT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CORT stands at 8.8B. In comparison, OREX has a market cap of 0. Regarding current trading prices, CORT is priced at $80.53 on the NASDAQ, while OREX trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CORT currently has a P/E ratio of 231.69, whereas OREX's P/E ratio is -0.14. In terms of profitability, CORT's ROE is +0.08%, compared to OREX's ROE of -0.54%. Regarding short-term risk, CORT is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for CORT.Check OREX's competition here